BridgeBio Pharma Inc [BBIO] stock is trading at $28.79, up 7.99%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 6.28% over the last week, with a monthly amount glided 12.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On September 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $46 on the stock. BMO Capital Markets initiated its recommendation with a Market Perform and recommended $37 as its price target on January 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $58. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating.
BridgeBio Pharma Inc [BBIO] stock has fluctuated between $21.62 and $44.32 over the past year. Currently, Wall Street analysts expect the stock to reach $47.2 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $28.79 at the most recent close of the market. An investor can expect a potential return of 63.95% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 217.76M for the trailing twelve months, which represents a drop of -33.22%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.48%, Pretax Profit Margin comes in at -2.05%, and Net Profit Margin reading is -2.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is 0.37 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.13 points at the first support level, and at 25.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.88, and for the 2nd resistance point, it is at 30.96.
Ratios To Look Out For
For context, BridgeBio Pharma Inc’s Current Ratio is 3.19. As well, the Quick Ratio is 3.19, while the Cash Ratio is 1.91. Considering the valuation of this stock, the price to sales ratio is 26.98.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Nov 19 ’24 when 27389.0 shares were sold. Secretary, Treasurer & CFO, STEPHENSON BRIAN C completed a deal on Nov 19 ’24 to sell 4156.0 shares. Meanwhile, Officer BRIAN STEPHENSON bought 4156.0 shares on Nov 19 ’24.
